Repligen (NASDAQ:RGEN) Reaches New 1-Year Low - Should You Sell?

Key Points

• New 52-week low: Repligen shares hit a one-year low of $109.50 and last traded at $114.06 on heavy volume, trading below its 50-day ($123.53) and 200-day ($145.82) moving averages.
• Analysts have cut price targets and ratings recently (Canaccord and Barclays lowered targets to $145), but the consensus remains a "Moderate Buy" with an average price target of $170.93.
• Fundamentals: Repligen posted an EPS beat ($0.49 vs. $0.44) and revenue of $197.9M (+18.1% YoY), guided FY2026 EPS to $1.93–2.01 (analysts ~1.97), and shows strong liquidity and heavy institutional ownership (about 97.64%).

Repligen Corporation (NASDAQ:RGEN - Get Free Report) hit a new 52-week low on Friday . The company traded as low as $109.50 and last traded at $114.06, with a volume of 2174671 shares traded. The stock had previously closed at $124.40.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on RGEN shares. Canaccord Genuity Group dropped their price objective on Repligen from $165.00 to $145.00 and set a "hold" rating on the stock in a research report on Monday. Barclays decreased their price target on shares of Repligen from $175.00 to $145.00 and set an "overweight" rating for the company in a research report on Tuesday, April 14th. Wall Street Zen cut shares of Repligen from a "buy" rating to a "hold" rating in a report on Saturday, February 28th. KeyCorp reiterated an "overweight" rating on shares of Repligen in a research note on Wednesday, February 25th. Finally, Weiss Ratings cut shares of Repligen from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Tuesday, March 3rd. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $170.93.

Repligen Stock Performance

The company has a current ratio of 8.37, a quick ratio of 7.12 and a debt-to-equity ratio of 0.26. The company has a market cap of $6.43 billion, a PE ratio of 134.19, a P/E/G ratio of 2.42 and a beta of 1.19. The firm's 50-day simple moving average is $123.53 and its two-hundred day simple moving average is $145.82.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.05. The business had revenue of $197.91 million during the quarter, compared to analysts' expectations of $192.23 million. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The business's quarterly revenue was up 18.1% on a year-over-year basis. During the same quarter last year, the company posted $0.44 earnings per share. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. As a group, research analysts anticipate that Repligen Corporation will post 1.97 earnings per share for the current fiscal year.

Institutional Trading of Repligen

Several large investors have recently added to or reduced their stakes in RGEN. United Capital Financial Advisors LLC acquired a new position in shares of Repligen in the third quarter valued at about $368,387,000. Opti Capital Management LP acquired a new stake in shares of Repligen during the fourth quarter worth about $2,399,209,000. Wasatch Advisors LP purchased a new stake in Repligen in the first quarter valued at approximately $146,513,000. Massachusetts Financial Services Co. MA purchased a new stake in Repligen in the fourth quarter valued at approximately $199,176,000. Finally, Price T Rowe Associates Inc. MD increased its holdings in Repligen by 31.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company's stock worth $753,603,000 after buying an additional 1,091,683 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

About Repligen

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.